Janney Montgomery Scott LLC Buys 5,982 Shares of Icon Plc $ICLR

Janney Montgomery Scott LLC boosted its holdings in shares of Icon Plc (NASDAQ:ICLR) by 29.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,145 shares of the medical research company’s stock after purchasing an additional 5,982 shares during the period. Janney Montgomery Scott LLC’s holdings in Icon were worth $3,803,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Transcend Capital Advisors LLC raised its position in Icon by 7.6% in the 1st quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company’s stock valued at $205,000 after purchasing an additional 83 shares during the last quarter. First National Bank Sioux Falls raised its position in Icon by 5.7% in the 2nd quarter. First National Bank Sioux Falls now owns 1,580 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 85 shares during the last quarter. Farther Finance Advisors LLC raised its position in Icon by 22.8% in the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 110 shares during the last quarter. Pinnacle Wealth Planning Services Inc. raised its position in Icon by 8.7% in the 1st quarter. Pinnacle Wealth Planning Services Inc. now owns 1,657 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 132 shares during the last quarter. Finally, Horizon Investments LLC raised its position in Icon by 23.7% in the 1st quarter. Horizon Investments LLC now owns 808 shares of the medical research company’s stock valued at $141,000 after purchasing an additional 155 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

Icon Stock Down 2.0%

NASDAQ:ICLR opened at $186.65 on Wednesday. Icon Plc has a 1 year low of $125.10 and a 1 year high of $303.69. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. The stock has a market cap of $15.07 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 2.82 and a beta of 1.23. The stock has a 50-day moving average price of $173.75 and a two-hundred day moving average price of $156.76.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the previous year, the firm earned $3.75 earnings per share. The company’s revenue was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. As a group, equities analysts expect that Icon Plc will post 13.38 earnings per share for the current year.

Analyst Ratings Changes

ICLR has been the subject of several research reports. Barclays lifted their target price on Icon from $180.00 to $190.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Jefferies Financial Group cut Icon from a “buy” rating to a “hold” rating and lowered their target price for the company from $220.00 to $175.00 in a research note on Tuesday, September 9th. Baird R W raised Icon from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a research note on Saturday, September 27th. Finally, Rothschild & Co Redburn raised Icon from a “neutral” rating to a “buy” rating and lifted their target price for the company from $184.00 to $236.00 in a research note on Wednesday, September 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Icon currently has an average rating of “Moderate Buy” and a consensus target price of $217.33.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.